2013
DOI: 10.1016/j.imbio.2012.10.007
|View full text |Cite
|
Sign up to set email alerts
|

Activated phenotype of circulating neutrophils in familial Mediterranean fever

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
19
2

Year Published

2014
2014
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 23 publications
(25 citation statements)
references
References 40 publications
4
19
2
Order By: Relevance
“…FMF attacks are characterised by neutrophilia and neutrophil infiltration to affected tissues 9 10. For this reason, we initially investigated NETs release by peripheral blood PMNs during periods of disease attack and remission.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…FMF attacks are characterised by neutrophilia and neutrophil infiltration to affected tissues 9 10. For this reason, we initially investigated NETs release by peripheral blood PMNs during periods of disease attack and remission.…”
Section: Resultsmentioning
confidence: 99%
“…However, little is known regarding the triggers of disease attacks, as well as the contribution of PMNs to the initiation of the attacks 1 2 10. To date, studies that describe the cellular expression or circulating levels of IL-1β during inflammatory attack, are either controversial or missing 9 43 44.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…27 The hallmark of the disease is recurrent, self-limiting febrile episodes of serosal and synovial inflammation and During inflammatory episodes, high number of abnormally activated polymorphonuclear neutrophils and monocytes circulate and influx into the affected sites. 28,29 Neutrophils are responsible for endothelial dysfunction, oxidative stress, and over production of adhesion molecules. 30 Moreover, attack-free periods of FMF are characterized by subclinical inflammation.…”
Section: Discussionmentioning
confidence: 99%
“…All samples were treated with RNaseOUT Recombinant Ribonuclease Inhibitor (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and maintained at -80˚C. cDNA synthesis and qPCR were performed as described previously (27). Briefly, cDNA synthesis was performed using a Transcriptor First Stand cDNA Synthesis kit (Roche Diagnostics) and stored at -20˚C prior to further use.…”
Section: Methodsmentioning
confidence: 99%